LHP3

General Information


DRACP ID  DRACP05922

Peptide Name   LHP3

Sequence  VPKDVNAAIA

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Induce apoptosis Tubulin Inhibitors



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Tubulin

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  FITC, 5(6)-carboxy fluorescence

C-terminal Modification  Free

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C44H76N12O14

Absent amino acids  CEFGHLMQRSTWY

Common amino acids  A

Mass  115789

Pl  6.34

Basic residues  1

Acidic residues  1

Hydrophobic residues  6

Net charge  0

Boman Index  -248

Hydrophobicity  58

Aliphatic Index  127

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 36240440

Title  Evolution of Potential Antimitotic Stapled Peptides from Multiple Helical Peptide Stretches of the Tubulin Heterodimer Interface: Helix-Mimicking Stapled Peptide Tubulin Inhibitors

Doi 0.1021/acs.jmedchem.2c01116

Year  2022

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.